Top Markets
Coin of the day
Anthem Biosciences Ltd. Anthem Biosciences Ltd.

Anthem Biosciences Ltd.

ANTHEM
Rank in Stocks #3337
Anthem Biosciences Ltd. operates as a technology-driven organization... Anthem Biosciences Ltd. operates as a technology-driven organization specializing in contract research, development, and manufacturing (CRDMO). The company's activities are organized into two primary divisions: CRDMO services and the production of Specialty Ingredients. Through its CRDMO segment, Anthem Biosciences offers comprehensive, full-lifecycle support for both novel chemical and biological entities. This support spans the entire development pipeline, from initial target identification and concept generation, through preclinical evaluation, the creation of development batches for all three phases of clinical trials, and ultimately, commercial-scale manufacturing. Their expertise covers a wide array of advanced therapeutic areas, including RNA-based therapies, antibody-drug conjugates, peptides, oligonucleotides, lipids, biologics, and biotherapeutics. They also employ specialized processes such as fermentation, biosynthesis, biotransformation, and flow chemistry. In its Specialty Ingredients division, Anthem Biosciences manufactures and supplies intricate, fermentation-derived active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2. The company's portfolio also encompasses microbial and mammalian biosimilars, a diverse range of probiotics (such as various species of bacillus, lactobacillus, bifidobacterium, streptococcus, and saccharomyces boulardii), and enzymes. Additionally, they produce key peptides like semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide, alongside nutritional actives, vitamin analogues, and other APIs. The company was established in Bengaluru, India, in 2006.
Share Price
$10.00
Market Cap
$5.62B
Change (1 day)
3.61%
Change (1 year)
4.87%
Country
IN
Trade Anthem Biosciences Ltd. (ANTHEM)

Category

P/E ratio for Anthem Biosciences Ltd. (ANTHEM)
P/E ratio as of 2026 TTM: 0
According to Anthem Biosciences Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Anthem Biosciences Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
-7.93 -
US
32.46 -
AU
- -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.